We have undertaken a study of novel naturally occuring
antimutagenic agents. Antimutagens are individual chemical
compounds that decrease the numbers of spontaneous or injury-
induced mutations in intact cell populations. This proposal is to
use short-term tests to screen for; isolate by use of bioassay
directed methodology; determine chemical structure by spectroscopic
and wet chemical methodology of; determine structure-activity
relations by systematic syntheses and chemical transformations of;
explore the biological properties of; and explore the molecular
mechanisms of action of novel antimutagens of natural origin. The
long-term objectives are to make potential chemopreventive agents
against genetic damage and, perhaps, cancer.
Using a bioassay specially developed for the purpose, Glycyrrhiza
glabra, a well known plant used by humans since ancient times for
its flavoring and medicinal properties, was shown to be
reproducably active. The activity was present in the phenolic
fractions and, after chromatographic resolution, the flavanoids
glabrene and, to a lesser extent, glabridin and glabrol, were found
to be the active constituents. The bioassay which produced these
successful results in this trial study is based upon the well known
Ames short-term Salmonella mutagenicity assay but modified through
the use of an alkylating agent (ethyl methanesulfonate) to induce
mutations.
Based upon this success, it is proposed to use the screen, with the
inclusion of other mutagenic treatments as well, to screen for
additional examples of natural antimutagenic substances in related
plants and to identify the active constituents. A program of
chemical modification accompanied by biotesting is proposed so as
to explore in a systematic way the relationship between structure
and activity in these novel series.
In addition to the insights into the mutagenic phenomenon and the
other biological areas where mutagenicity is believed to play an
important role (ageing, heredity, carcinogenicity,
environmental concerns) these compounds may have some potential in
preventive human medicine.
No Sub Projects information available for 5R01CA043713-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA043713-02
Patents
No Patents information available for 5R01CA043713-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA043713-02
Clinical Studies
No Clinical Studies information available for 5R01CA043713-02
News and More
Related News Releases
No news release information available for 5R01CA043713-02
History
No Historical information available for 5R01CA043713-02
Similar Projects
No Similar Projects information available for 5R01CA043713-02